

Protea Fund - Sectoral Biotech Opportunities Fund - PF EUR

ISIN LU1176838347

As of 31/03/2024
Marketing material

Investment Objective

The Sub-Fund invests primarily in innovative biotech companies developing novel drugs in therapeutic areas with large unmet medical needs. Investments are made across all market caps, with significant exposure to mid- and small-cap biotech companies, due to their high degree of innovation. Novel and differentiated treatments benefit from a favorable regulatory and commercial environment, with the potential for shortened development timelines, rapid market adoption as well as strong pricing and operating margins. Innovation in biotech has created large new markets, and tremendous commercial potential remains in many diseases and novel therapeutic modalities, such as mRNA and gene therapy.

Investment Policy

The manager specializes in the area of healthcare investments and employs a bottom-up, research-intensive investment approach. The security selection process is based on primary research, analysis of industry and company fundamentals, and in-depth due diligence on companies to assess their scientific, business, and financial aspects. ESG and sustainability criteria are integrated throughout the process.

Sectoral Asset Management is a
Signatory of:



SFDR Classification¹

Article 6

Article 8

Article 9

¹Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on Sustainability-related disclosures in the financial services sector (SFDR).

Risk Category SRI




General Information

Portfolio management	Sectoral Asset Management Inc.
Fund domicile, legal structure, SFDR	Luxembourg, UCITS, Art. 8
Currency of the fund / shareclass	USD / USD
Fund size	EUR 25.57 mio
Net asset value (NAV) / share	EUR 9.14
Distribution policy	Reinvested
Launch date fund / shareclass	31.05.2016 / 31.05.2016
ISIN / WKN / VALOR	LU1176838347 / A14NHE / 26967215
Bloomberg	PRSBPFE
Management fee	1.80%
Ongoing charges (incl. Mgmt. fee) as of 31.12.2022	2.16%
Maximum entry / switching / exit fee ²	2.00%/1.50%/0.00%
Swing pricing	Yes
Minimum Investment	EUR 0
Benchmark	Nasdaq Biotechnology
Benchmark ESG	Nasdaq Biotechnology

²Refer to fund distributor for actual applicable fees, if any.

Not all costs are displayed. Please refer to the prospectus and PRIIPS KID for further details.

Indexed Performances (%)




Source: FundPartner Solutions (Europe) S.A. - Part of Pictet Group

Past performance before 26.01.2024 are referring to the fund Variopartner SICAV which has been merged into Protea Fund as of the 29.01.2024. Please note that neither the investment policy, the benchmark, or the investment manager changed, only the name of the fund, management company and custodian changed.


Past performance must not be considered an indicator or guarantee of future performance. Any tables, graphs, or charts relating to past performance included are used only to illustrate the performance of indices, strategies, or specific funds for the historical periods shown and should not be used as a basis for making any investment decision. All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies. Future performance is subject to taxation which depends on the personal situation of each investor, and which may change in the future.

Sector Breakdown



Source: FundPartner Solutions (Europe) S.A. - Part of Pictet Group

Geographical Breakdown



Source: FundPartner Solutions (Europe) S.A. - Part of Pictet Group

Risk Metrics/Risk Information³

Volatility, annualized	16.08%	Jensen’s alpha	-5.39%
Sharpe ratio	-0.32	Beta	0.98
Information ratio	-1.29	Tracking error, ex-post	4.17%

³Calculated over 3 years

Source: FundPartner Solutions (Europe) S.A. - Part of Pictet Group

Market Commentary

In March, the MSCI World Index was up 3.2%. The Nasdaq Biotech Index was up 0.1%, underperforming large cap healthcare at +2.4% (as measured by the MSCI World Healthcare Index). Positive clinical updates included those from Crinetics (acromegaly and carcinoid syndrome), Viking (obesity) and Stoke (Dravet Syndrome). Negative or mixed reports included those from Amylyx (ALS), Acadia (negative symptoms of schizophrenia) and Spruce (congenital adrenal hyperplasia). In regulatory news, the FDA approved Madrigal’s Rezdiffra for NASH, Akebia’s Vafseo for anemia due to chronic kidney disease and Idorsia’s Tryvio for high blood pressure in patients not adequately controlled in combination with other antihypertensives. FDA advisory committees recommended the approval of drugs from Geron for MDS, and CAR-T treatments from 2Seventy and Legend/JNJ in multiple myeloma. On the corporate front, M&A activity included AstraZeneca’s acquisition of radiopharmaceuticals company Fusion for USD2bn (97% premium) and endocrine play Amolyt (private) for USD800m.

Top contributors: Moderna +16% on new trials being initiated in skin cancer with partner Merck; Amgen +4% on recovery from prior weakness; AstraZeneca +6% on investor positioning into upcoming Capital Markets Day.

Top detractors: Amylyx -82% on failed confirmatory phase III in ALS; Acadia -24% on failed phase III for the treatment of negative symptoms of schizophrenia; Eyepoint -24% on consolidation after period of strength amid weakness in smid-cap.


Notable transactions: The position in Karuna was liquidated due to the closing of its acquisition.

Currency Breakdown



Source: FundPartner Solutions (Europe) S.A. - Part of Pictet Group

Top Holdings




Source: FundPartner Solutions (Europe) S.A. - Part of Pictet Group

ESG Risk Rating


	Rating	Coverage	Category
Portfolio	23.8	95%	Medium
Benchmark ESG	24.2	98%	Medium

Categories for ESG Risk: Negligible (0-9.99), Low (10-19.99), Medium (20-29.99), High (30-39.99), Severe (40 and higher)



Portfolio


Breakdown (by Asset Type)



Coverage (by Asset Type)

Asset type	Eligible	Covered	Not Covered
Equities	Yes	95.4%	3.9%
Cash	No	-	0.7%
Total		95.4%	4.6%

Distribution (Portfolio, weight in %)



Source : Sustainalytics

Corporate Governance

	Rating
Portfolio	55
Benchmark ESG	55

6 Pillars of Corporate Governance

Ownership & Shareholder Rights	42
Remuneration	44
Stakeholder Governance	54
Board Management Quality	60
Audit & Financial Reporting	64
Board Structure	70

Level of risk is distributed from 0 to 100, 0 being the highest and 100 the lowest.
Source : Sustainalytics

Physical Climate Risk

	Rating
Portfolio	64
Benchmark ESG	65


3 Pillars of Physical Climate Risk

Market Risk	75
Operations Risk	62
Supply Chain Risk	46

Level of risk is distributed from 0 to 100, 0 being the lowest and 100 the highest.
Source : 427

Greenhouse Gas Emission

Carbon emission



Carbon emission in tonnes of CO₂ (Scope 1, 2 & 3)
Carbon footprint and carbon intensity in tonnes of CO₂ per million CHF (Scope 1, 2 & 3)
Source : Sustainalytics

	Carbon emissions*	Carbon footprint	Carbon intensity
Portfolio	167	7	51
Benchmark ESG	192	8	84

* GHG emission per EVIC

Product Involvement (Portfolio, weight in %)

Energy

Thermal coal	0.0%
Shale energy	0.0%
Oil sands	0.0%
Oil & gas	0.0%
Nuclear power	0.0%
Arctic oil & gas exploration	0.0%

Weapons

Small arms	0.0%
Military contracting	0.0%
Controversial weapons	0.0%

Other Activities

Tobacco	0.0%
Pesticides	0.0%
Genetically modified plants and seeds	0.0%
Gambling	0.0%
Adult entertainment	0.0%

Source : Sustainalytics



Methodologies

ESG Risk Rating

ESG Risk Rating measures the degree to which a company's economic value is at risk driven by ESG factors or, more technically speaking, the magnitude of a company's unmanaged material ESG risks.

Corporate Governance

Corporate Governance evaluates the governance structures, practices and behaviors of companies and their ability to build sustainable long-term value that can be delivered to stakeholders and shareholders in a fair and transparent manner.

GHG (Greenhouse Gas) Emissions

Scope 1 Emissions: Direct Greenhouse emissions that are generated from production processes which are owned and/or controlled by the company (ie: fuel combustion, company vehicles, fugitive emissions...).

Scope 2 Emissions: Indirect Greenhouse emissions associated with the purchase of energy (ie: electricity, heat or steam...).

Scope 3 Emissions: All indirect emissions arising from the activities of an organisation. This includes emissions from both suppliers and/or consumers (ie: purchased goods/services, travel, waste disposal, transportation and distributions, leased assets, investments...).

Carbon footprint: Aggregation of Scope 1, 2 and 3 GHG emissions of a company relative to its enterprise value.

Carbon intensity: Aggregation of Scope 1, 2 and 3 GHG emissions of a company relative to its sales or revenues.

Physical Climate Risk

Physical Climate Risk assesses the exposure of companies that may potentially be negatively affected by the physical impacts of climate change.

Controversies

ESG Controversies analysis of underlying companies is based on incidents and events that may pose a business or reputational risk due to the potential impact on stakeholders, the environment, or the company's operations.

Product Involvement

Product involvement provides research on companies' involvement in certain types of products and services. This enables screening approaches according to specific criteria such as ethical, impact, compliance or ESG risk considerations.

This research tracks both direct involvement in a product in one or more ways such as production, distribution or related services and indirect involvement in a product through ownership in an involved company.

Address

SECTORAL ASSET MANAGEMENT INC
1010 SHERBROOKE ST. WEST, # 1610
MONTREAL, QUEBEC
CANADA H3A 2R7

Contact

Antoine Blondin
+41.22.316.66.38
antoine@sectoral.com

Disclaimer

Swiss representation agent: FundPartner Solutions Suisse S.A., Route des Acacias 60, CH -1211 Geneva 73 / Swiss paying agent: Banque Pictet & Cie SA, Route des Acacias 60, CH -1211 Geneva 73.

The fund mentioned in the present document (hereinafter the "Fund") does not guarantee that the data contained in this report (hereinafter the "Data") are complete, accurate, or free of errors or omissions. The Fund is not liable for this report under any circumstances. This marketing communication is distributed by the Fund or authorised distribution agencies for information purposes only and does not constitute an offer to subscribe for shares of the Fund. Subscriptions of the Fund, an investment fund under Luxembourg law (SICAV), should in any event be made solely on the basis of the current offering prospectus, the Key Investor Information Document ("KIID"), the articles of incorporation and the most recent annual or semi-annual report and after seeking the advice of an independent finance, legal, accounting and tax specialist. Interested parties may obtain the abovementioned documents free of charge from the local entity mentioned above and from the offices of the Fund at 15, avenue John F. Kennedy, L1855 Luxembourg. You can obtain a summary of investors rights to the following link : <https://www.group.pictet/media/sd/176b100ab205a6e6aef82b0250138f889675b903>. The evaluation of the securities and other instruments in this report is based on rates taken from the customary sources of financial information (hereinafter the "Data Providers") and may be updated without notice. The Data Providers do not guarantee the adequacy, accuracy, timeliness or completeness of their data and information (hereinafter the "Third Party Data"). The Data Providers do not make any representation regarding the advisability of any investment and do not sponsor, promote, issue, sell or otherwise recommend or endorse any investment. An investment in a sub-fund of the Fund carries various risks which are explained in the offering prospectus.

The Third Party Data used for the present report is provided on an "as is" basis and all warranties, including without limitation, the implied warranties of merchantability and fitness for a particular purpose are excluded by the Data Providers. In no event shall the Data Providers, and any of its affiliates or any other person involved in or related to compiling, computing or creating the Third Party Data be liable for any damages relating to the Third Party Data, including, without limitation, damages resulting from any use of or reliance on the Third Party Data. The Data can only be read and/or used by the person to whom they are addressed. The Fund is not liable for the use, transmission or exploitation of the Data. Therefore, any form of reproduction, copying, disclosure, modification and/or publication of the Data is under the sole liability of the addressee of this report, and no liability whatsoever will be incurred by the Fund. The addressee of this report agrees to comply with the applicable laws and regulations in the jurisdictions where they use the Data.